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of SCT-ineligible patients; in second-line (post-onset of relapsed/refractory MM), 
lenalidomide/dexamethasone (33%) and bortezomib/dexamethasone (15%) were 
most common for patients previously receiving SCT (similar results reported for 
patients not receiving SCT). More than half of physicians estimated that typical 
second-line treatment duration is < 6 months, with progression cited (~75% of 
respondents) as the main reason for second-line discontinuation. For high-risk 
patients, 52% of physicians judged median survival to be < 10 months from RRMM 
onset. CONCLUSIONS: Bortezomib-based regimens are the predominant choice of 
first-line MM treatment; while bortezomib is also frequently chosen in second-line 
(post-RRMM onset), lenalidomide-based regimens are the most common. Survival 
prospects for RRMM patients remain limited, particularly for high-risk patients, 
and second-line therapy is typically of short duration (< 6 months). Patient-level 
studies are needed to formally characterize unmet medical needs suggested in 
our findings for European RRMM patients.
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OBJECTIVES: Initial endocrine therapy (ET) is preferred for most post-menopausal 
women with hormone receptor positive human epidermal growth factor receptor 
2 negative metastatic breast cancer (HR+/HER2- mBC), and guidelines recommend 
reserving chemotherapy (CT) for patients with symptomatic visceral disease or no 
clinical benefit after 3 sequential ET regimens. This study describes treatment pat-
terns among post-menopausal HR+/HER2- mBC patients previously treated with 
adjuvant therapy (recurrent patients) or not (de novo patients). METHODS: Charts 
from a network of US community-based oncology practices were reviewed for 
post-menopausal women with HR+/HER2- mBC who progressed to mBC between 
1/1/2004 and 9/30/2010. Extracted chart data included demographic characteristics, 
treatment history, and outcomes. RESULTS: Patients (n= 144) had a median age of 
65 years at mBC diagnosis. They received a median of 2 lines of ET, and < 10% had 
3 or more lines of ET before receiving CT. De novo patients (n= 69) and recurrent 
patients (n= 75) received a median of 2 lines and 1 line of ET, respectively. The 
recurrent group had a lower proportion of patients receiving 1st-line single agent 
ET compared with the de novo group (65% vs. 71%). Unlike de novo patients, who 
had non-steroidal aromatase inhibitors (NSAIs) as the most frequent 1st-line ET 
(letrozole (35%), anastrozole (26%)), recurrent patients predominantly received 
fulvestrant (23%) in the 1st-line setting, possibly due to prior adjuvant NSAI. In 
addition, a higher proportion of recurrent patients received CT as 1st-line therapy 
compared with de novo patients (27% vs. 20%). CONCLUSIONS: The majority of 
de novo patients received 1st-line NSAIs, but recurrent patients were less likely 
to receive NSAIs and more likely to receive 1st-line CT. Recurrent patients also 
received fewer total lines of ET. Most mBC patients did not receive the guideline-
recommended 3 lines of ET. The unmet need for improved ET options was par-
ticularly pronounced among recurrent patients.
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OBJECTIVES: To evaluate the efficacy and safety of FDA-approved biologics for 
moderate-to-severe Crohn’s disease (CD). METHODS: We conducted a literature 
search using PubMed, EMBASE, and Cochrane library, and identified articles from 
inception to October 10, 2014. The combination of search terms included: “inflixi-
mab,” “adalimumab,” “certolizumab pegol,” “vedolizumab,” and “Crohn’s disease.” 
Studies were selected if they were randomized placebo-controlled trials > /= 50 
weeks of follow-up; that evaluated one or more biologics of interest, provided 
results about clinical remission (defined as CD Activity Index< 150 points), serious 
infections and/or serious adverse events; and was conducted in adults. The princi-
pal aim was to compare clinical remission at the end of the study period between 
biologics. Secondary aims included the probability of experiencing a serious infec-
tion or serious adverse event. Bayesian network meta-analyses were performed 
to synthesize results; and comparisons were summarized using odds ratios (OR) 
and 95% credible intervals (CrI). RESULTS: Among 324 articles identified, 11 met 
inclusion criteria. The odds of achieving clinical remission were greater with adali-
mumab than with vedolizumab (OR= 1.33; 95%CrI: 0.67-2.42), infliximab (OR= 1.40; 
95%CrI: 0.86-2.53) and certolizumab pegol (OR= 1.23; 95%CrI: 0.72-2.29); all not 
statistically significant. Similarly, the odds of clinical remission were greater with 
certolizumab pegol than with vedolizumab (OR= 0.91; 95%CrI: 0.48-1.60) and inf-
liximab (OR= 1.18; 95%CrI: 0.68-1.92); all not statistically significant. Certolizumab 
pegol had the highest probability of serious infections (0.053%) followed by ved-
olizumab (0.022%), infliximab (0.010%), and adalimumab (0.008%). Vedolizumab 
had the highest probability of serious adverse events (19%) followed by certoli-
zumab pegol (10%), infliximab (10%), and adalimumab (7%). CONCLUSIONS: We 
did not find any statistically significant differences between biologics in clinical 
remission, serious infections, and serious adverse events, which highlights the 
importance for comparative effectiveness research (CER) in this area. CER will be 
able to guide clinical and formulary decision-makers in selecting biologics with 
high value for CD.
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OBJECTIVES: Colorectal cancer (CRC) ranks third in prevalence and cancer deaths 
among all cancers in the United States. Nearly one fourth of CRC patients are diag-
nosed at metastatic stage (mCRC), which has a poor prognosis and an overall survival 
of 5% to 8% at five years. Over the last decade multiple chemotherapies and targeted 
biologics have been approved for mCRC and patients receive an array of these treat-
ments in various combinations, with limited evidence. The study examines current 
usage patterns by line of treatment for elderly mCRC patients. METHODS: A retro-
spective observational cohort study was conducted for mCRC patients diagnosed 
from January 2004 through December 2009 using the Surveillance Epidemiology 
and End Results-Medicare linked database. Systemic chemotherapies and targeted 
biologics currently approved by the Food and Drug Administration for treatment 
of mCRC patients were included. The first three lines of treatment administered to 
elderly mCRC patients were empirically identified. RESULTS: The most common 
first line of treatment for mCRC patients (n= 4,603) was bevacizumab + fluorouracil 
+ oxaliplatin (24%), followed by fluorouracil + oxaliplatin (23%). Bevacizumab + fluo-
rouracil + oxaliplatin (18%) and bevacizumab + fluorouracil + irinotecan (15%) were 
the most administered second line of treatments, while cetuximab + irinotecan and 
bevacizumab + fluorouracil + irinotecan were the commonly administered third line 
regimens (15% each). Of 4,603 mCRC patients who received first a line of treatment, 
2,708 (59%) continued to receive a second line of treatment, 1,480 (32%) received 
a third line of treatment, and 1,895 (41%) did not receive any further line of treat-
ment. CONCLUSIONS: In accordance with current recommendations and previous 
studies, fluorouracil + oxaliplatin/irinotecan based regimens with bevacizumab 
were the most common first and second line treatments. Further exploration of the 
comparative effectiveness of line of treatments sequencing may yield important 
information for improving the quality of cancer treatment.
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OBJECTIVES: Little data from real-world clinical settings in Europe are available 
describing treatment patterns and survival of relapsed/refractory multiple mye-
loma (RRMM) patients. This study begins to address this knowledge gap using data 
from a brief physician survey. METHODS: A cross-sectional survey of 61 physicians 
treating RRMM in France (n= 21), Germany (n= 20), and the United Kingdom (n= 20) 
was conducted in November 2014. The survey collected physicians’ opinions on 
typical treatment patterns and survival of RRMM patients in the relapse/refrac-
tory setting (i.e., following disease progression during/after completion of first-
line therapy). Analyses were descriptive. RESULTS: Specialty distribution among 
the respondents was 44% hematology, 51% onco-hematology, and 5% medical 
oncology. Teaching hospitals were the most common practice setting (59%). The 
respondents’ mean (SD) past-year multiple myeloma (MM) caseload was 53.0 (33.0) 
patients (range: 12-150); 21% of these patients were reported to have high-risk 
disease based on ISS stage and cytogenetics. Bortezomib-based regimens were 
first-line treatment for 73% of stem cell transplant (SCT)-eligible patients and 60% 
